Expression of ps2 protein and estrogen and progesterone receptor status in breast cancer

Acta Cytologica

Volumn 41, Issue 3, 1997, Pages 713-716

  Ioakim Liossi, Anna ^a,b   Karakitsos, Petros ^a,b   Markopoulos, Christos ^a,b,c   Aroni, Kyriaki ^a,b   Delivelioti, Kalliopi ^a,b   Gogas, John ^a,b   Kyrkou, Kalliopi ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Estrogen receptors; Progesterone receptors; PS2 protein

Indexed keywords

ESTROGEN RECEPTOR; GROWTH FACTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030969229     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000332690     Document Type: Article

References (26)

1. Baker ME: Oestrogen-induced pS2 protein is similar to pancreatic spasmolytic polypeptide and the Kringle domain. Biochem J 1988;253:307-311
2. Berger U, Wilson P, Thethi S, McClelland RA, Greene GI, Coombes RC: Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and oestrogen receptor. Cancer Res 1989;49:5176-5179
3. Bloom HJB, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-377
4. Cavailles V, Augereau P, Garcia M, Rochefort H: Estrogens and growth factors induce the mRNA of the 52K-pro-cathep-sin D secreted by breast cancer cells. Nuclei Acids Res 1988;16:1903-1919
5. Detre S, King N, Salter J, MacLennan K, McKinna JA, Dowsett M: Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. J Clin Pathol 1994;47:240-244
6. Foekens JA, Van Putten WLJ, Portengen H, De Koning HY, Thirion B, Alexieva-Figusch J, Klijn JGM: Prognostic value of pS2 and cathepsin-d in 710 human primary breast tumors: Multivariate analysis. J Clin Oncol 1993;11:899-908
7. Gromback G, Ingenhorst A, Goehring UJ, Scharl A, Neuhaus W, Moebus V, Schaeffer HJ: Expression of pS2 protein in breast cancer. Arch Gynecol Obstet 1993;253:183-192
8. Henry SA, Nicholson S, Hennessy C, Lennard TWJ, May FEB, Westley BR: Expression of the oestrogen regulated pNR-2mRA in human breast cancer: Relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Br J Cancer 1990;61:32-38
9. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FEB: pNR-2/pS2 immunohistochemical staining in breast cancer: Correlation with prognostic factors and endocrine response. Br J Cancer 1991;63:615-622
10. Ibrahim NBN, Padfield CJH, Rees EJ, Wilson Y, Cawthorn SJ: Immunocytochemistry in the assessment of pS2 protein expression in fine needle aspiration cytology from breast carcinoma. Cytopathology 1993;4:323-330
11. Koerner FC, Goldberg DE, Edgerton SM, Schwartz LH: pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 1992;52:183-188
12. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10:7895-7903
13. Mori K, Fujii R, Kida N, Ohta M, Hayashi K: Identification of a polypeptide secreted by human breast cancer cells (MCF-7) as the human estrogen-responsive gene (pS2) product. Biochem Biophys Res Commun 1988;155:366-371
14. Mori K, Fujii R, Kida N, Takahashi H, Ohkubo S, Fujino M, Ohta M, Hayashi K: Complete primary structure of the human estrogen-responsive gene (pS2) product. J Biochem 1990;107:73-76
15. Nunez AM, Berry M, Imler JL, Chambon P: The 58flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J 1989;8:823-829
16. Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980;46:2884-2888
17. Pallud C, Doussal V, Pichon MF, Prud'homme JF, Hacene K, Milgrom E: Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology 1993;23:249-256
18. Pichon MF, Milgrom E: Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumors. Br J Cancer 1992;65:895-897
19. Predine J, Spyretos F, Prud'homme JF, Andieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors and normal breast tissues. Cancer 1992;69:2116-2123
20. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 1987;84:9243-9247
21. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991;51:624-628
22. Spyretos F, Andrieu C, Hacene K, Chambon P, Rio MC: pS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 1994;69:394-397
23. Thim L: A new family of growth factor-like peptides. "Trefoil" disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP) and frog skin peptides (spas-molysins). FEBS Lett 1989;250:85-90
24. Thompson AM, Howkins RA, Elton RA, Steel CM, Chetty U, Carter DC: pS2 is an independent factor of good prognosis in primary breast cancer. Br J Cancer 1993;68:93-96
25. Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LA: pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival. Breast Cancer Res Treat 1992;21:111-119
26. Wysocki SJ, Hahnel E, Masters A, Smith V, MacCartneny AJ, Hahnel R: Detection of pS2 messenger RNA in gynecological cancers. Cancer Res 1990;50:1800-1802